ProfileGDS5678 / 1449348_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 82% 79% 81% 79% 78% 75% 76% 81% 83% 85% 85% 83% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6073880
GSM967853U87-EV human glioblastoma xenograft - Control 25.9878182
GSM967854U87-EV human glioblastoma xenograft - Control 35.540379
GSM967855U87-EV human glioblastoma xenograft - Control 45.9877381
GSM967856U87-EV human glioblastoma xenograft - Control 55.5391979
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1597678
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8815175
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.0314676
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7786781
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1328783
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3326685
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.416185
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0661283
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9887883